VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Weber on CheckMate-238 Compared With Other Trials in Melanoma

Jeffrey S. Weber, MD, PhD
Published: Thursday, Sep 28, 2017



Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the results of CheckMate-238 compared with other adjuvant trials for patients with melanoma.

It is difficult to compare the results of the CheckMate-238 study compared to any other adjuvant study for patients with melanoma, states Weber. Other than the ipilimumab (Yervoy) and nivolumab (Opdivo) study, there are no data to give a frame of reference.

Most adjuvant studies only treat patients with stage IIIa, IIIb, and IIIc melanoma; whereas, in the CheckMate-238 study, it was a group of higher-risk patients, explains Weber.
 


Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the results of CheckMate-238 compared with other adjuvant trials for patients with melanoma.

It is difficult to compare the results of the CheckMate-238 study compared to any other adjuvant study for patients with melanoma, states Weber. Other than the ipilimumab (Yervoy) and nivolumab (Opdivo) study, there are no data to give a frame of reference.

Most adjuvant studies only treat patients with stage IIIa, IIIb, and IIIc melanoma; whereas, in the CheckMate-238 study, it was a group of higher-risk patients, explains Weber.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x